RAMUCIRUMAB News

RAMUCIRUMAB currently has 8 news articles, with 20 predicted indications.

This page combines the AI-predicted indications for RAMUCIRUMAB with the latest health news. Indications highlighted in orange have recent news coverage.

Drug Information

Evidence level: L5
Predicted indications (20):
- adenocarcinoma of liver and intrahepatic biliary tract (99.0%)
- liver cancer (99.0%)
- squamous cell carcinoma of liver and intrahepatic biliary tract (99.0%)
- hepatocellular carcinoma (99.0%)
- pediatric hepatocellular carcinoma (99.0%)
- non-small cell lung carcinoma (disease) (99.0%)
- fibrolamellar hepatocellular carcinoma (99.0%)
- gastric adenocarcinoma (99.0%)
- undifferentiated carcinoma of liver and intrahepatic biliary tract (99.0%)
- lung cancer (99.0%)
- uterine ligament adenocarcinoma (100.0%)
- endocervical carcinoma (100.0%)
- adenoid cystic carcinoma of the cervix uteri (100.0%)
- uterine ligament serous adenocarcinoma (99.9%)
- signet ring cell variant cervical mucinous adenocarcinoma (99.9%)
- cervical adenosquamous carcinoma, glassy cell variant (99.9%)
- uterine ligament endometrioid adenocarcinoma (99.9%)
- uterine ligament clear cell adenocarcinoma (99.9%)
- uterine ligament mucinous adenocarcinoma (99.9%)
- intestinal variant cervical mucinous adenocarcinoma (99.9%)